Skip to main content
Premium Trial:

Request an Annual Quote

Genome Pharmaceuticals Wins $5.7 Million in Government Financing

Premium

MUNICH--Genome Pharmaceu ticals, a functional genomics company here, secured DM 10 million in government funding, half from a state agency and half from a federal agency, in a recent financing round. The company announced plans to establish a unique combination of three genomic databases holding detailed information on genes, expression profiles, and protein interaction networks to identify and validate novel drug targets for diseases that cannot be treated effectively. Those plans will be carried out in collaboration with other unnamed biotechnology and pharmaceutical companies, the company said.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.